

CCSVI- Chronic Cerebrospinal Venous Insufficiency

E. Mark Haacke, PhD

*McMaster University
Hamilton, Ontario*

*Wayne State University
Detroit, Michigan 48201*



WAYNE STATE UNIVERSITY



Acknowledgements

- ▶ David Hubbard, MD for MS data
- ▶ Salvatore Sclafani, MD, for images
- ▶ Monte Harvill, MD for slides
- ▶ Liu Jiangtao, MD for MS data

- ▶ Wei Feng, PhD for processing flow data
- ▶ Gabriela Trifan, MD for image analysis
- ▶ David Utriainen, for image analysis
- ▶ Meng Li, MS, for perfusion TSM data
- ▶ Jaladhar Neelavalli, PhD for SWIM support

MULTIPLE SCLEROSIS

In Canada:




- ▶ 55,000-75,000 MS patients
- ▶ most common neurological disease affecting young adults
- ▶ ~1,000 new cases of MS diagnosed each year
- ▶ Economic impact > **\$1 billion** annually
- ▶ **In the USA multiply by roughly 8!**
- ▶ **Throughout the world 2.5 million people may be affected by MS**

MULTIPLE SCLEROSIS

Facts about MS:

- ▶ Cause unknown...there is no cure
- ▶ 2 to 3 times more women than men
- ▶ The symptoms - mild to debilitating :
 - vision problems;
 - loss of balance and/or coordination,
 - extreme fatigue,
 - speech or memory failure;
 - muscle stiffness and paralysis.



CCSVI

Chronic cerebro-spinal venous insufficiency

Zamboni noted narrowing of the veins at the neck or spine was restricting blood flow and potentially high levels of iron were accumulating in the brain (65 case studies)




Paolo Zamboni demonstrated that there were major venous abnormalities in MS patients



Zamboni P et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2009;80:392-399.


IRON IN MULTIPLE SCLEROSIS LESIONS: (data courtesy of Liu Jiangtao, Beijing, China)

Phase from SWI data showing ring structures around MS lesions likely representing macrophage activity and a leakage of iron at the edge of the lesion.




Using perfusion weighted imaging (PWI), it can be shown that most MS lesions show the same vascular abnormalities:


Anatomic evidence of lesions from FLAIR imaging



PWI shows all MS lesions have the same vascular characteristics



Recall 1935 work on venous obstruction



Tracey Putnam, Boston City Hospital, developed an experimental **dog model of venous obstruction to study MS**. His work supports the recent rediscovery of this concept by Dr. Paolo Zamboni of Italy.

He stated:

“The similarity between such lesions and many of those seen in cases of multiple sclerosis in man is so striking that the conclusion appears almost inevitable that **venular obstruction is the essential immediate antecedent to the formation of typical sclerotic plaques.**”

Putnam (1935). Studies in multiple sclerosis: encephalitis and sclerotic plaques produced by venular obstruction. Archives of Neurology and Psychiatry. 33: 929-940.

Venous Interventions: Dr. Monte Harvill

- ▶ Dialysis access venous interventions (angioplasty and stents)
- ▶ Venous thrombolysis
- ▶ Vena cava filters
- ▶ Venous access devices
- ▶ Pelvic congestion syndrome
- ▶ Varicose vein therapy

Interventional radiologists perform these procedures every day in Canada.

Complications of PTA

Ludyga T et al. Endovascular treatment for chronic cerebrospinal venous insufficiency: is the procedure safe? Phlebology. 2010; 25: 286-95.

- ▶ Access site complications
- ▶ Thrombosis
- ▶ Vessel rupture
- ▶ Distal embolization
- ▶ Flow-limiting dissection

Venous PTA: Dr. Monte Harvill

Why use percutaneous transluminal angoplasty?


- ▶ Always the first choice for hemodynamically significant venous stenosis
- ▶ Valves (stuck, stiff, extra-competent)
- ▶ Membranous lesions
- ▶ Ostial lesions

The role of magnetic resonance imaging (MRI) in diagnosing and monitoring patients with multiple sclerosis (MS)

Part of the McDonald criteria is based on the number of non-enhancing and enhancing lesions seen in MR scans.

But there is much more possible today:

- ▶ Monitoring iron content
- ▶ Visualizing arteries and veins
- ▶ Measuring blood flow in each major vessel
- ▶ Quantifying perfusion to brain tissue



Why perform MR imaging before and after treatment?


We need to:

- ▶ monitor lesions and iron content
- ▶ monitor arterial, venous and CSF flow changes
- ▶ use the 3D data to help plan the intervention
- ▶ serve as a baseline to study the anatomy and flow after treatment if complications develop and generally monitor lesions, flow and iron over time

Left: Stenosis at the stump of the LIJV with collateral input from the vertebral system
Right: String like jugular in the RIJV



Collateral development on the same side as the stenosis




MR examples of CCSVI in MS patients where pre-treatment planning would reveal significant data that could affect how the veins are accessed.







Stenosed RIJV

Choosing transverse planes for flow quantification



Flow Quantification




Categorization of 126 AFI MS patients vs. Normals w.r.t. $R = \text{total IJV}/\text{total arterial flow}$:

Type I: $0.67 < R < 1$


Type II: $0.33 < R < 0.67$

Type III: $0 < R < 0.33$



Doepp F et al. "How does the blood leave the brain? A systematic ultrasound analysis of cerebral venous drainage patterns," *Neurorad.*, 46: 565-570; 2004.

Pre-post treatment of a young Canadian with severe MS:
What about the 1000s of Canadians who have been treated
and need follow up? All MS patients get an MR anyway!



*Using MRI and angiography, it is clear that
MS patients HAVE venous abnormalities*

Possible characterization of venous abnormalities in CCSVI: 60 measures

Anatomical markers		Possible Criteria Threshold		Valves	
<i>Presence/Engorgement of Collaterals</i>		<i>Present/Absent/Engorgement/Symmetry/Tortuous Shape</i>		Constrast Discontinuity at Confluence	
External Jugular Vein		Absent/ Engorgement of CSA < 49mm ² / Symmetry/Tortuous shape		Biphasic Flow	
Anterior Jugular Vein		Absent/Engorgement of CSA < 25mm ² / Symmetry/Tortuous shape		Jetting Effect	
Vertebral Vein		Absent/Engorgement of CSA < 25mm ² / Symmetry/Tortuous shape		Developmental Anomalies	
Vertebral Plexus		Engorgement; Symmetry		Narrowing at the Confluence	
Deep Cervical Vein		Absent/ Engorgement of CSA < 25mm ² / Symmetry/Tortuous shape			
<i>Stenosis in Neck</i>		<i>Present/Absent</i>		SWI Markers	
IJV stenosis superior to C3 (UL)		CSA < 12.5mm ²		<i>Small veins</i>	
IJV stenosis inferior to C3 (LL)		CSA < 25.0mm ²		Visibility of veins	
Truncular Venous Malformation		Present/Absent			
Missing IJV (s)		One or Both IJVs missing including superior/inferior jugular bulbs		<i>Iron content</i>	
Missing Vertebral Veins		Present/Absent at the C6 level		Pulvinar Thalamus	
Missing Deep Cervical Veins		Present/Absent		Putamen	
				Globus Pallidus	
<i>Stenosis in Thoracic Cavity</i>		<i>Present/Absent</i>		Caudate Nucleus	
Azygous stenosis		Stenosis of 75% of Azygous CSA		Red Nucleus	
Azygous compression between heart and spine		Present/Absent		Substantia Nigra	
Missing Azygous		Present/Absent		Dentate Nucleus	
Missing Hemi-azygous		Present/Absent		Micro-bleeds	
Missing both Azygous and Hemi-azygous		Present/Absent		Lesions	
Azygous engorgement		CSA>1cm ²			
Quantitative Flow Markers		Possible Criteria Threshold		Qualitative Flow Markers	Preferred MR Imaging Method
<i>C6 level flow</i>		<i>Present/Absent</i>		Contrast Discontinuity through vessel	3D TRI
Dominant IJV: Sub-Dominant IJV		> 4:1		Loss of signal	2D TOF
Dominant vein: Sub-Dominant vein		> 4:1		Inhomogeneous signal at confluence	2D TOF
Total venous flow		< 8 ml/s			
Total IJV flow		< 5 ml/s			
Total percent of venous flow carried by IJV		< 32%			
High velocity of flow through veins		> 25 cm/s			
Low velocity of flow through veins		< 1 cm/s			
<i>C2 level flow</i>		<i>Present/Absent</i>			
Dominant IJV: Sub-Dominant IJV		> 5:1			
Dominant vein: Sub-Dominant vein		> 5:1			
<i>Reflux</i>		<i>Present/Absent</i>			
Reflux of flow in IJV		> 10%			
Percent of CDC that IJV demonstrates low flow and reflux flow		> 30%			
% of CDC Vertebral Vein shows reflux		> 30%			
% of CDC Deep Cervical Vein shows reflux		> 30%			
% of CDC External Jugular Vein shows reflux		> 30%			

Conclusions

- ▶ Canada can be a leader in this direction but must have:
- ▶ 1) proper follow up for patients who have had treatment
- ▶ 2) a national registry to monitor patient outcomes
 - Minimal to no funding
- ▶ 3) a national trial of on the order of 1000 normals and 1000 patients marrying ultrasound, MRI and venous angiography
 - This requires dedicated funding just for this CCSVI study.
 - One avenue to fund this might be via a centers-of-excellence programme.
- ▶ If Canada takes action now, it can have answers in two years.